Hanmi Pharm to Contract Manufacture Genexine's COVID-19 Vaccine
[Asia Economy Reporter Ji Yeon-jin] Hanmi Pharmaceutical announced on the 18th that it has signed a contract for the consignment production of Genexine's COVID-19 vaccine.
The contract amount is 24,533,520,000 KRW, which is 2.28% of last year's sales of 1,075,800,000,000 KRW.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- Billionaire 'Mango' Founder Dies in Fall... Vice Chairman Son Arrested
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This contract involves undertaking the commercialization production process and analytical method development of Genexine's COVID-19 vaccine (GX-19N), pilot production of the commercial drug, and preparation of documents (CTD) required for approval. The vaccine will be sold domestically and in Indonesia.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
